Adherex adherex.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

A team of experts dedicated to identifying, developing and commercializing novel cancer therapeutics A diversified portfolio of innovative cancer compounds in preclinical and clinical development Three products in advanced development, each representing a major therapeutic and commercial opportunity Adherex is focused on developing solutions to unmet needs in cancer Long-term complications Treatment resistance and debilitating side effects

A team of experts dedicated to identifying, developing and commercializing novel cancer therapeutics A diversified portfolio of innovative cancer compounds in preclinical and clinical development Three products in advanced development, each represent...Show all

Company (Alive / Active)

Phone: 919-484-8484

Fax:

4620 Creekstone Drive
Suite 200
Durham, 27703
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Adherex $39.5M Jul 25, 2005
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Adherex Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

YM BioSciences

Mississauga, Ontario, Canada
AcquiredYM BioSciences is a life sciences product development company advancing a diverse portfolio of hematology and cancer-related products at various stages of development. In February 2013, YM BioSciences was acquired by Gilead Sciences. The valuation of YM BioSciences was undisclosed. Other terms of the deal were not released.Login to see details

Cell Therapeutics

Seattle, Washington, United States
Alive / ActiveCTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In the company's pursuit of making cancer more treatable, they are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer. Login to see details
See all 15 competitors